ADC Therapeutics S.A. (ADCT)

NYSE • Healthcare

$1.44

-$0.16 (-10.0%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$1.58

Previous Close$1.44

Day Range$1.43 - $1.59

Avg. Volume (3M)1.5M

Market Cap$183.8M

52 Week Range

$0.78$4.98

Next EarningsIn 17 daysNov 10, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$19.2M100%

Gross Profitminus cost of goods$16.8M88%

In plain terms: out of every $100 in revenue, ADC Therapeutics S.A. currently loses $86.

Fundamentals & Financials

Revenue (TTM)

$78.7M

Net Income (TTM)

-$96.9M

EPS (TTM)

-$0.66

ROA (TTM)

-34.69%

Current Ratio

3.03

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-38.9%Q3 2025-$0.5

+25.0%Q4 2025-$0.3

+87.5%Q1 2026-$0.04

-10.5%Q2 2026-$0.21

+49.1%Q3 2026-$0.11

Nov 10

in 17 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +49.1%

ADC Therapeutics beat consensus on both revenue and earnings in the second fiscal quarter of 2026, reported Aug. 13, as revenue rose 2.2% to about $19.2 million and EPS was -$0.11 versus a -$0.22 estimate, +49%. Gross profit reached about $16.9 million, with gross margin near 88%, while operating loss was about $25.4 million and operating margin was around -132%. Net income improved 70.8% to about -$16.6 million from about -$56.6 million a year earlier, and EPS improved from -$0.50. Operating cash flow was negative about $11.8 million. Consensus for the next period calls for EPS of -$0.21 on revenue of $18.9 million.

Next report — what to expect

ADC Therapeutics S.A. (ADCT) reports earnings on November 10, 2026. Wall Street is looking for EPS of -$0.21 on revenue of $18.7 million. For trailing context, revenue increased +2.2% year over year last quarter. ADCT has beaten EPS in 5 of 8 most recent quarters, making profit/loss and topline delivery key watch items.

View full earnings history

About ADC Therapeutics S.A.

ADC Therapeutics S.A. develops antibody-drug conjugates for blood cancers and solid tumors, placing it in the biotechnology part of healthcare. Listed on the NYSE as ADCT, it records $81.4 million of revenue in FY2025, centered on ZYNLONTA and a pipeline of oncology candidates.

Name

ADC Therapeutics S.A.

CEO

Ameet Mallik

Website

www.adctherapeutics.com

Industry

Healthcare

Year Founded

2011

Employees

191

Today's Snapshot

AI-generated

ADCT closed 10% below yesterday's close, in line with a weaker sector.

Trading Volume

Below 10d avg (1.4M)

vs S&P 500 Today

Strong Underperformance

-9.48%

Updated: October 23, 2026 at 20:23 UTC

Technical Indicators

2 Buy3 Neutral3 Sell

ADCT presents a bearish technical picture with the stock trading around 1.44 and remaining well below the 200-day average near 2.53, which underscores a longer-term down bias. Short-term momentum has turned soft and the MACD is flat, while ATR shows elevated volatility at roughly 0.15 and ADX near 24 suggests a borderline trending environment. Price is below short-term moving averages, and the cumulative volume balance is deeply negative, highlighting distribution. Technical takeaway: indicators align with an overall sell bias, with elevated volatility and weak longer-term trend confirmation.

All signals

EMA (5 indicators)$1.37 - $2.44
Sell
RSI (14)51.65
Neutral
Stochastic %K (14, 3, 3)51.54
Neutral
MACD Level (12, 26)0.08
Neutral

Peers & Related Assets

OMEROmeros Corporation

$16.57-1.7%

ALMSAlumis Inc.

$6.78-0.6%

FDMT4D Molecular Therapeutics, Inc.

$10.8-8.9%

QSIQuantum-Si incorporated

$1.4+21.7%

RAPTRAPT Therapeutics, Inc.

LXRXLexicon Pharmaceuticals, Inc.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.